drug · small molecule
zasocitinib
Phase 3updated 5mo agoby $TAK TAKEDA PHARMACEUTICAL CO LTD🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 7 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying zasocitinib
- phase2A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
- phase3A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- phase3Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- phase3A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
- phase2A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
- phase3A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
- phase3A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
- phase2A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
News(10)
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 7d ago
- Takeda’s long-term R&D head announces exit after major pipeline reorganizationA few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change as its long-time R&D head plans his exit.biospace · 24d ago
- Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successesAndy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June.fiercebiotech · 25d ago
- Schrödinger births new immunology and inflammation biotech, Tectora TherapeuticsSchrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.fiercebiotech · 26d ago
- Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitorA phase 2b lupus trial of Alumis’ envudeucitinib has missed its primary and secondary endpoints. But the biotech is still moving the TYK2 inhibitor into phase 3 in the autoimmune disease, pointing…fiercebiotech · 1mo ago
- FDA OKs Takeda, Protagonist drug for rare blood cancerThe clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.biopharma_dive · 1mo ago
- Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunityThe approval of rusfertide—now to be branded Mimrylo—for polycythemia vera marks a key win for Takeda, which now has crossed the FDA finish line for two of three critical product launches slated fo…biospace · 1mo ago
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 1mo ago
- Takeda’s narcolepsy nod opens orexin doorsOrzeyful is the first orexin agonist cleared by the FDA, and is the first narcolepsy therapy that addresses the full host of disease symptoms. It is "likely to reshape the treatment paradigm” for t…biospace · 1mo ago
Data sources
last refreshed 34m ago
Found something off?
comments(0)
5-min edit window · permanent after that